Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
Neoplasms
DRUG: GSK3901961|DRUG: GSK3845097|DRUG: GSK4427296|DRUG: Cyclophosphamide|DRUG: Fludarabine
Number of Participants Enrolled Across Sub Studies, Number of Participants Randomized across sub studies are presented., Day -7
This study is a master protocol. It has two sub studies registered as 209012 Sub Study 1 (NCT06048705) and 209012 Sub Study 2 (NCT05943990).